However, the endocytic activity of the CDH17 monoclonal antibody is much lower than that of the GUCY2C monoclonal antibody, which may reduce the anti-tumor activity of the CDH17 monoclonal antibody ADC. This evidence concerns the gene CDH17 and neoplasm.